ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 16
- Registration Number
- NCT02805374
- Locations
- 🇯🇵
Site JP00001, Tokyo, Japan
Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 144
- Registration Number
- NCT02805348
- Locations
- 🇯🇵
Site JP00004, Gifu, Japan
🇯🇵Site JP00001, Ibaraki, Japan
🇯🇵Site JP00003, Kanagawa, Japan
Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT02796118
- Locations
- 🇯🇵
Site JP00001, Osaka, Japan
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 190
- Registration Number
- NCT02786979
- Locations
- 🇨🇳
Site CN00006, Tianjin, Tianjin, China
🇨🇳Site CN00001, Beijing, Beijing, China
🇨🇳Site CN00003, Shanghai, Shanghai, China
A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT02780141
- Locations
- 🇯🇵
Site JP00003, Aichi, Japan
🇯🇵Site JP00005, Aichi, Japan
🇯🇵Site JP00002, Niigata, Japan
A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 56
- Registration Number
- NCT02780726
- Locations
- 🇯🇵
Site JP00005, Fukuoka, Japan
🇯🇵Site JP00004, Aichi, Japan
🇯🇵Site JP00003, Nagano, Japan
A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 164
- Registration Number
- NCT02779764
- Locations
- 🇯🇵
Site JP00001, Yamaguchi, Japan
🇯🇵Site JP00004, Gunma, Japan
🇯🇵Site JP00021, Hokkaido, Japan
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT02760342
- Locations
- 🇯🇵
Site JP00001, Kagoshima, Japan
Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 73
- Registration Number
- NCT02753894
- Locations
- 🇯🇵
Site JP00006, Ibaraki, Japan
🇯🇵Site JP00008, Ibaraki, Japan
🇯🇵Site JP00002, Miyagi, Japan
Pharmacokinetic Study of ASP1517 With Kremezin®
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 34
- Registration Number
- NCT02693613
- Locations
- 🇯🇵
Site JP00001, Tokyo, Japan
© Copyright 2024. All Rights Reserved by MedPath